Hsbc Hldgs Plc Spons Adr (HSBC) Position Maintained by Janney Capital Management Llc; Gilead Sciences (GILD) Stock Rose While Crossvault Capital Management Has Trimmed Position by $1.54 Million

May 18, 2018 - By Vivian Park

HSBC Holdings plc (NYSE:HSBC) Logo

Crossvault Capital Management Llc decreased its stake in Gilead Sciences (GILD) by 29.81% based on its latest 2017Q4 regulatory filing with the SEC. Crossvault Capital Management Llc sold 21,625 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 50,925 shares of the health care company at the end of 2017Q4, valued at $3.65M, down from 72,550 at the end of the previous reported quarter. Crossvault Capital Management Llc who had been investing in Gilead Sciences for a number of months, seems to be less bullish one the $88.49 billion market cap company. The stock increased 0.67% or $0.4519 during the last trading session, reaching $68.0519. About 1.26M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since May 18, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.




Janney Capital Management Llc increased its stake in Hsbc Hldgs Plc Spons Adr (HSBC) by 22.2% based on its latest 2017Q4 regulatory filing with the SEC. Janney Capital Management Llc bought 74,943 shares as the company’s stock declined 7.84% with the market. The institutional investor held 412,571 shares of the savings institutions company at the end of 2017Q4, valued at $21.31 million, up from 337,628 at the end of the previous reported quarter. Janney Capital Management Llc who had been investing in Hsbc Hldgs Plc Spons Adr for a number of months, seems to be bullish on the $198.06 billion market cap company. The stock increased 0.12% or $0.06 during the last trading session, reaching $49.7. About 367,518 shares traded. HSBC Holdings plc (NYSE:HSBC) has risen 17.01% since May 18, 2017 and is uptrending. It has outperformed by 5.46% the S&P500.

More important recent HSBC Holdings plc (NYSE:HSBC) news were published by: Seekingalpha.com which released: “HSBC Holdings Plc (HSBC) Q1 2018 Results – Earnings Call Transcript” on May 04, 2018, also Seekingalpha.com published article titled: “First trade finance transaction via blockchain”, Benzinga.com published: “Edward Achtner” on May 15, 2018. More interesting news about HSBC Holdings plc (NYSE:HSBC) was released by: Benzinga.com and their article: “JPMorgan, HSBC, Citigroup, Early Warning Execs Talk Fintech Collaboration” with publication date: May 15, 2018.

Among 11 analysts covering HSBC Holdings (NYSE:HSBC), 3 have Buy rating, 2 Sell and 6 Hold. Therefore 27% are positive. HSBC Holdings had 20 analyst reports since September 30, 2015 according to SRatingsIntel. The firm has “Buy” rating by Bank of America given on Thursday, August 4. The rating was upgraded by UBS to “” on Wednesday, September 30. The company was downgraded on Tuesday, March 29 by BNP Paribas. The stock has “Underweight” rating by Morgan Stanley on Monday, February 8. The stock of HSBC Holdings plc (NYSE:HSBC) earned “Market Perform” rating by Bernstein on Monday, November 21. The stock of HSBC Holdings plc (NYSE:HSBC) earned “Neutral” rating by UBS on Wednesday, September 14. The stock has “Equal-Weight” rating by Morgan Stanley on Tuesday, December 6. The firm has “Buy” rating by Citigroup given on Tuesday, November 8. On Tuesday, November 29 the stock rating was initiated by Credit Suisse with “Neutral”. The company was downgraded on Thursday, January 14 by Macquarie Research.

Janney Capital Management Llc, which manages about $3.30B and $2.34 billion US Long portfolio, decreased its stake in Aes Corp (NYSE:AES) by 955,065 shares to 17,656 shares, valued at $191,000 in 2017Q4, according to the filing. It also reduced its holding in Indl Sel Sect Spdr Etf (XLI) by 7,669 shares in the quarter, leaving it with 430,206 shares, and cut its stake in Amgen Inc (NASDAQ:AMGN).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Lipotoxicity And NASH: Gilead’s Actions Speak Louder Than Words” on May 09, 2018, also Seekingalpha.com with their article: “Kite Pharma continues buildout for cell therapy manufacture” published on May 15, 2018, Seekingalpha.com published: “Gilead: What A Disaster” on May 08, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead Sciences: Resist Sentiment, Stop Speculating And Invest” published on May 15, 2018 as well as Bizjournals.com‘s news article titled: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” with publication date: May 17, 2018.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 130 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, April 29 by Citigroup. The firm has “Buy” rating given on Thursday, February 25 by Citigroup. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Needham on Tuesday, July 26. On Tuesday, September 6 the stock rating was upgraded by Jefferies to “Buy”. The stock has “Outperform” rating by Oppenheimer on Wednesday, July 29. The company was maintained on Friday, December 4 by Wells Fargo. Credit Suisse maintained the shares of GILD in report on Monday, August 28 with “Buy” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Outperform” rating given on Tuesday, January 16 by Wells Fargo. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, September 14. Credit Suisse has “Outperform” rating and $95 target. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Wednesday, September 9 by Jefferies.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It worsened, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Palisades Hudson Asset Mngmt Limited Partnership reported 0.15% stake. Fincl Architects has 0.13% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,853 shares. Hap Trading Limited Co has 0.13% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Arvest Comml Bank Trust Division has 232,086 shares for 1.16% of their portfolio. Sequoia Financial Advsr holds 89,796 shares or 0.68% of its portfolio. 17,448 were accumulated by Rand Wealth Limited Liability Company. Exchange Cap Management owns 130 shares for 0% of their portfolio. Creative Planning has invested 0.06% in Gilead Sciences, Inc. (NASDAQ:GILD). Tt invested 0.96% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Lingohr Partner Asset Management Gmbh reported 0.78% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Marco Invest Mgmt Lc owns 203,135 shares for 2.22% of their portfolio. Jnba Finance Advsrs reported 7,807 shares. Puzo Michael J holds 0.53% or 17,896 shares. Amica Mutual has 85,234 shares. Lynch Assocs In stated it has 0.43% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD).

Since January 2, 2018, it had 0 insider purchases, and 22 selling transactions for $44.80 million activity. Cogan John Francis also sold $434,384 worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, April 6. 100,000 shares were sold by Meyers James R, worth $8.02M on Tuesday, January 16. MARTIN JOHN C also sold $3.66M worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Monday, April 2. Washington Robin L sold $401,566 worth of stock. Another trade for 60,000 shares valued at $4.68 million was made by WILSON GAYLE E on Friday, February 9.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.